Michael E. Thase, MD

Choosing Medications for Treatment-Resistant Depression

June 24, 2015

What can you do for your patients with depression who show partial response or no response to treatment? Follow a discussion by expert faculty about how altering levels of...

Michael E. Thase, Thomas L. Schwartz

Commentary

US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine

January 28, 2015

Michael E. Thase

Academic Highlights

Overview of Vortioxetine (Brintellix)

December 24, 2014

Understand what is Vortioxetine (Brintellix), an antidepressant for major depressive disorder and treatment-resistant depression.

Alan F. Schatzberg, Michael E. Thase, George I. Papakostas, et al

Original Research

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

October 28, 2014

Michael E. Thase, Anita H. Clayton, Kristen Focht, et al

Commentary

Depression: Addressing Partial Response After First-Line Antidepressant Treatment

September 25, 2014

Maurizio Fava, Andrew A. Nierenberg, Michael E. Thase

Educational Activity

Translating Clinical Science Into Effective Therapies

June 15, 2014

Michael E. Thase

Article

A Review of Vilazodone, Serotonin, and Major Depressive Disorder

January 9, 2014

The efficacy and safety of vilazodone was established in 2 positive Phase III clinical trials in adult patients with MDD. This article provides a brief overview of the serotonin...

Michael E. Thase, Kerri A. Pierz

Original Research

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

November 26, 2013

Susan G. Kornstein, Madhukar H. Trivedi, Michael E. Thase, et al

Original Research

The Prevalence and Severity of Depressive Symptoms Along the Spectrum of Unipolar Depressive Disorders: A Post Hoc Analysis

November 15, 2013

Kimberly A. Yonkers, Michael E. Thase, David J. Kupfer, et al

Educational Activity

Residual Symptoms and the Risk of Relapse in Major Depression

November 15, 2013

Michael E. Thase

Supplement Article

The Multifactorial Presentation of Depression in Acute Care

October 29, 2013

Michael E. Thase

Article

The Multifactorial Presentation of Depression in Acute Care

October 15, 2013

Michael E. Thase

Choosing Medications for Treatment-Resistant Depression

US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine

Overview of Vortioxetine (Brintellix)

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Depression: Addressing Partial Response After First-Line Antidepressant Treatment

Translating Clinical Science Into Effective Therapies

A Review of Vilazodone, Serotonin, and Major Depressive Disorder

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

The Prevalence and Severity of Depressive Symptoms Along the Spectrum of Unipolar Depressive Disorders: A Post Hoc Analysis

Residual Symptoms and the Risk of Relapse in Major Depression

The Multifactorial Presentation of Depression in Acute Care

The Multifactorial Presentation of Depression in Acute Care

ELSEWHERE:

FOLLOW US:

Michael E. Thase, MD

Choosing Medications for Treatment-Resistant Depression

US Food and Drug Administration's Review of the Novel Antidepressant Vortioxetine

Overview of Vortioxetine (Brintellix)

Desvenlafaxine 50 and 100 mg/d Versus Placebo for the Treatment of Major Depressive Disorder: A Phase 4, Randomized Controlled Trial

Depression: Addressing Partial Response After First-Line Antidepressant Treatment

Translating Clinical Science Into Effective Therapies

A Review of Vilazodone, Serotonin, and Major Depressive Disorder

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

The Prevalence and Severity of Depressive Symptoms Along the Spectrum of Unipolar Depressive Disorders: A Post Hoc Analysis

Residual Symptoms and the Risk of Relapse in Major Depression

The Multifactorial Presentation of Depression in Acute Care

The Multifactorial Presentation of Depression in Acute Care

Insightful. Evidence-based. Human-centered.

Subscribe to readmore articles

Subscribe to read
more articles